| PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity SR Gordon, RL Maute, BW Dulken, G Hutter, BM George, MN McCracken, ... Nature 545 (7655), 495-499, 2017 | 1886 | 2017 |
| Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy AA Barkal, K Weiskopf, KS Kao, SR Gordon, B Rosental, YY Yiu, ... Nature immunology 19 (1), 76-84, 2018 | 470 | 2018 |
| Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging RL Maute, SR Gordon, AT Mayer, MN McCracken, A Natarajan, NG Ring, ... Proceedings of the National Academy of Sciences 112 (47), E6506-E6514, 2015 | 389 | 2015 |
| Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy A Chhabra, AM Ring, K Weiskopf, PJ Schnorr, S Gordon, AC Le, HS Kwon, ... Science translational medicine 8 (351), 351ra105-351ra105, 2016 | 180 | 2016 |
| Computational design of an α-gliadin peptidase SR Gordon, EJ Stanley, S Wolf, A Toland, SJ Wu, D Hadidi, JH Mills, ... Journal of the American Chemical Society 134 (50), 20513-20520, 2012 | 149 | 2012 |
| Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging AT Mayer, A Natarajan, SR Gordon, RL Maute, MN McCracken, AM Ring, ... Journal of Nuclear Medicine 58 (4), 538-546, 2017 | 119 | 2017 |
| Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity L Cui, SY Chen, T Lerbs, JW Lee, P Domizi, S Gordon, Y Kim, G Nolan, ... Nature Communications 11 (1), 2795, 2020 | 87 | 2020 |
| Surgical adhesions in mice are derived from mesothelial cells and can be targeted by antibodies against mesothelial markers JM Tsai, R Sinha, J Seita, N Fernhoff, S Christ, T Koopmans, GW Krampitz, ... Science translational medicine 10 (469), eaan6735, 2018 | 80 | 2018 |
| High affinity PD-1 agents and methods of use AM Ring, A Kruse, A Manglik, IL Weissman, RL Maute, MN McCracken, ... US Patent 9,546,206, 2017 | 50 | 2017 |
| High affinity PD-1 agents and methods of use AM Ring, A Kruse, A Manglik, IL Weissman, RL Maute, MN McCracken, ... US Patent 9,562,087, 2017 | 46 | 2017 |
| Compositions and methods for treating celiac sprue disease J Siegel, D Baker, SRA Gordon, IS Pultz, EJ Stanley, SJ Wolf US Patent 9,707,280, 2017 | 5 | 2017 |
| High affinity PD-1 agents and methods of use AM Ring, A Kruse, A Manglik, IL Weissman, RL Maute, MN McCracken, ... US Patent 10,800,830, 2020 | 4 | 2020 |
| HSC transplantation in an immunocompetent host without radiation or chemotherapy A Chhabra, A Ring, K Weiskopf, PJ Schnorr, S Gordon, AC Le, HS Kwon, ... Experimental Hematology 43 (9), S57, 2015 | 4 | 2015 |
| Compositions and Methods for Treating Celiac Sprue Disease J Siegel, D Baker, SRA Gordon, IS Pultz, EJ Stanley, SJ Wolf US Patent App. 18/513,879, 2024 | | 2024 |
| High affinity pd-1 agents and methods of use AM Ring, A Kruse, A Manglik, IL Weissman, RL Maute, MN McCracken, ... US Patent App. 18/482,223, 2024 | | 2024 |
| High affinity PD-1 agents and methods of use AM Ring, A Kruse, A Manglik, IL Weissman, RL Maute, MN McCracken, ... US Patent 11,814,419, 2023 | | 2023 |
| Compositions and Methods for Treating Celiac Sprue Disease J Siegel, D Baker, SRA Gordon, IS Pultz, EJ Stanley, SJ Wolf US Patent App. 17/114,294, 2021 | | 2021 |
| Compositions and methods for treating celiac sprue disease J Siegel, D Baker, SRA Gordon, IS Pultz, EJ Stanley, SJ Wolf US Patent 10,874,720, 2020 | | 2020 |
| Pd-1-midler med høj affinitet og anvendelsesfremgangsmåder A Kruse, A Manglik, IL Weissman, RL Maute, MN Mccracken, S Gordon, ... | | 2020 |
| High affinity pd-1 agents and methods of use AM RING, A KRUSE, A MANGLIK, IL Weissman, RL MAUTE, ... | | 2020 |
